aTyr Pharma Stock (NASDAQ:ATYR)
Previous Close
$0.92
52W Range
$0.64 - $7.29
50D Avg
$0.85
200D Avg
$2.54
Market Cap
$85.00M
Avg Vol (3M)
$2.01M
Beta
0.56
Div Yield
-
ATYR Company Profile
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HYFT | MindWalk Holdings Corp. |
| QNCX | Quince Therapeutics, Inc. |
| CAMP | CAMP4 Therapeutics Corporation |
| MGX | Metagenomi, Inc. Common Stock |
| RPTX | Repare Therapeutics Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| DTIL | Precision BioSciences, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| RLMD | Relmada Therapeutics, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |